Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC
Ivonescimab is the only bispecific immunotherapy antibody currently undergoing Phase III registration trials for IO-resistant lung cancer.
In recent years, immunotherapy has achieved significant progress in the treatment of NSCLC. PD-1/L1 inhibitors, whether used as monotherapy or in combination with platinum-based chemotherapy, have become the standard first-line treatment for advanced NSCLC in patients without driver mutations. However, despite these advances, 60%-70% of patients experience disease progression within the first year of treatment.
Currently, there are no approved standard treatment options for IO-resistant NSCLC. Docetaxel is recommended in both China's and international treatment guidelines for immunotherapy-resistant (IO-resistant) NSCLC. However, docetaxel's monotherapy efficacy in the IO-resistant NSCLC patients remains limited. Several Phase III clinical trials investigating IO-resistant lung cancer, including immunotherapy combination therapies studies and ADC therapy studies, have failed to demonstrate positive results.
Mechanistic studies suggest that PD-1 therapy can restore the immune system's anti-tumor activity, while anti-VEGF therapy alleviates VEGF-mediated immune suppression and promotes T-cell infiltration. When combined, these two therapies may produce synergistic effects. Ivonescimab simultaneously targets both PD-1 and VEGF pathways, reversing the immune-suppressive tumor microenvironment and reactivating anti-tumor immune responses. These synergistic mechanisms provide a scientific rationale for using ivonescimab to treat IO-resistant tumors. Furthermore, the positive efficacy and safety data demonstrated in a Phase II study in this indication underscore the significant therapeutic potential of ivonescimab in this difficult to treat patient population.
The ivonescimab regimen has demonstrated remarkable efficacy and excellent safety across multiple tumor types. The ongoing AK112-305/HARMONi-8A Phase III study targeting IO-resistant NSCLC is expected to offer a novel and highly effective treatment option for patients with IO-resistant NSCLC, in line Akesos ' 'Immuno-2.0' strategy.
As the world's leading PD-1/VEGF bispecific antibody, ivonescimab has achieved extensive population coverage for core indications in NSCLC and is positioned across multiple lines of treatment, with the potential to reshape the overall treatment landscape for advanced NSCLC.
Forward-Looking Statement of Akeso, Inc.This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
About AkesoAkeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.
For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.
View original content:https://www.prnewswire.com/news-releases/akeso-announces-completion-of-first-dosing-in-phase-iii-clinical-trial-of-ivonescimab-pd-1vegf-combination--therapy-for-immunotherapy-resistant-nsclc-302518092.html
SOURCE Akeso, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025. The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. In data presented at ASH 2024, GPC-100 appears to be well differentiated in terms of the speed with which it mobilizes stem cells compared to currently approved stem cell mobilization treatments. Dr. Muthalagu Ramanathan, Director of the Myeloma Program and Medical Co-Director of the Blood and Marrow Transplant and CAR-T Program at U Mass Memorial Health noted that 'traditionally, patients undergoing mobilization are required to come, as an outpatient, the night before their procedure to receive the mobilization injection — a process that adds logistical challenges. The study drug GPC100 needed to be administered just 45 minutes before stem cell collection and resulted in a successful mobilization, significantly improving the patient experience. This is a true blessing for our frail myeloma patients.' In addition to multiple myeloma and a planned Phase 1 study in acute myeloid leukemia (AML) patients, the company is also in discussions for potential collaborations that would utilize GPC-100's rapid and safe mobilization of stem cells in cell and gene therapy settings. About GPC-100 GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, GPC-100 may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., GPC-100 became part of Exicure's pipeline following the company's acquisition in January 2025. In addition to multiple myeloma, GPC-100 is also being considered in acute myeloid leukemia (AML) and other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company's lead program, GPC-100, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit
Yahoo
3 hours ago
- Yahoo
Xtalks Announces its Life Science Webinar Calendar for August 2025
Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply chain and preclinical. TORONTO, Aug. 1, 2025 /PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field! Visit to see our upcoming webinars: CELL AND GENE THERAPYAugust 22 - How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround CLINICAL TRIALSAugust 7 - Improving Clinical Tech Adoption: Site-Centric ApproachesAugust 13 - Accelerating Clinical Research with Master Protocols: Challenges and Benefits to Complex Trial DesignsAugust 14 - Designing Innovative Trials: Navigating Dose Optimization in Oncology CombinationsAugust 15 - AI in Clinical Trials: Early Use Cases and Innovations COMMERCIALIZATION & HEORAugust 19 - 5 Critical Questions to Ask Before Applying AI to Real-World Data DRUG DISCOVERY & DEVELOPMENTAugust 7 - Oral Dosage Innovation for Pediatric Drug DeliveryAugust 7 - Cancer Drug Discovery: A Synthetic Lethality Approach Using Integrated PlatformsAugust 12 - Radiotracers and ADC Targeting: Scientific Insights for In Vivo Validation and Clinical TransitionAugust 13 - AI in Drug Discovery & Development: Hype, Reality and What Comes NextAugust 21 - Dose Escalation: Optimizing Cohort Management in Early-Phase DevelopmentAugust 26 - AI in Bioprocessing Today — Accelerate. Predict. Deliver. HEALTHCAREAugust 20 - Beyond Diagnosis: The Real-World Impact of AVISE Testing on Lupus, Rheumatoid Arthritis, and Autoimmune Disease Care LABORATORY TECHNOLOGYAugust 6 - Precision Matters: The Critical Role of Accurate Liquid Handling in the Lab MEDICAL DEVICEAugust 25 - Transforming Medical Imaging with AI: Open Tools, Faster Insights PATIENT RECRUITMENT & RETENTIONAugust 20 - Transforming Patient Recruitment: AI and Digital Strategies to Engage the Unreachable 95%August 27 - Enhancing Patient Recruitment in Clinical Research: A Personalized and Engaged Journey PHARMA MANUFACTURING & SUPPLY CHAINAugust 14 - Biofermentation Success Through pH and DO Management PRECLINICALAugust 26 - Advanced In Vivo Efficacy Models for Preclinical Success ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit Contact:Ayesha RashidXtalks ( Tel: +1 (416) 977-6555 x371Email: arashid@ View original content to download multimedia: SOURCE Xtalks Inicia sesión para acceder a tu cartera de valores
Business Upturn
3 hours ago
- Business Upturn
Frequency Electronics Announces 2025 Quantum Sensing Summit in New York City
MITCHEL FIELD, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. ('FEI' or the 'Company') (NASDAQ-FEIM), a leading provider of precision timing and frequency control products, today announced it will host the 2025 Quantum Sensing Summit on October 29–30, 2025, in New York City. The event will bring together leaders from government, industry, and research to accelerate the transition of quantum sensing technologies from the lab to mission-ready deployment. Building on the success of the inaugural 2024 summit, this year's two-day program will feature keynotes, panels, and technical sessions highlighting enabling technologies such as Rydberg and NV-diamond sensors, photonic integrated circuits (PICs), frequency combs, and ultra-low-noise oscillators. 'Quantum sensing is at the heart of the next technological revolution,' said Dr. Tom McClelland, CEO of Frequency Electronics. 'This summit is designed to forge the partnerships and strategies that turn today's breakthroughs into tomorrow's deployable solutions.' The summit is expected to attract 100–150 participants, including key government decision-makers, program managers, and industry innovators, providing a unique forum for collaboration and policy influence in the emerging quantum technology landscape. About Frequency Electronics Frequency Electronics, Inc. (FEI) is a world leader in the design, development and manufacture of high precision timing, frequency generation and RF control products for space and terrestrial applications. FEI's products are used in satellite payloads and in other commercial, government and military systems including C4ISR and electronic warfare, missiles, UAVs, aircraft, GPS, secure communications, energy exploration and wireline and wireless networks. FEI-Zyfer provides GPS and secure timing capabilities for critical military and commercial applications; FEI-Elcom Tech provides Electronic Warfare ('EW') sub-systems and state-of-the-art RF and microwave products. FEI has received over 100 awards of excellence for achievements in providing high performance electronic assemblies for over 150 space and DOD programs. The Company invests significant resources in research and development to expand its capabilities and markets. FEI's Mission Statement: 'Our mission is to transform discoveries and demonstrations made in research laboratories into practical, real-world products. We are proud of a legacy which has delivered precision time and frequency generation products, for space and other world-changing applications that are unavailable from any other source. We aim to continue that legacy while adapting our products and expertise to the needs of the future. With a relentless emphasis on excellence in everything we do, we aim, in these ways, to create value for our customers, employees, and stockholders.' Forward-Looking Statements The statements in this press release regarding future earnings and operations and other statements relating to the future constitute 'forward-looking' statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our inability to integrate operations and personnel, actions by significant customers or competitors, general domestic and international economic conditions, reliance on key customers, continued acceptance of the Company's products in the marketplace, competitive factors, new products and technological changes, product prices and raw material costs, dependence upon third-party vendors, other supply chain related issues, increasing costs for materials, operating related expenses, competitive developments, changes in manufacturing and transportation costs, the availability of capital, the outcome of any litigation and arbitration proceedings, and failure to maintain an effective system of internal controls over financial reporting. The factors listed above are not exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the Securities and Exchange Commission. The Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2024, filed on August 2, 2024 with the Securities and Exchange Commission includes additional factors that could materially and adversely impact the Company's business, financial condition and results of operations, as such factors are updated from time to time in our periodic filings with the Securities and Exchange Commission, which are accessible on the Securities and Exchange Commission's website at Moreover, the Company operates in a very competitive and rapidly changing environment. New factors emerge from time to time and it is not possible for management to predict the impact of all these factors on the Company's business, financial condition or results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not rely on forward-looking statements as a prediction of actual results. Any or all of the forward-looking statements contained in this press release and any other public statement made by the Company or its management may turn out to be incorrect. The Company expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact information: Dr. Thomas McClelland, President and Chief Executive Officer; Steven Bernstein, Chief Financial Officer; TELEPHONE: (516) 794-4500 ext.5000 WEBSITE: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
